INFLAMMATORY BOWEL DISEASE (IBD) is a chronic inflammatory disease of the intestine with an unclear etiological mechanism. Currently, the paradigm proposed is a feed-forward synergistic dysregulation of the mucosal epithelial barrier, the mucosal immune system, and gut microbiota (2, 6, 52) . Metagenomic and genome-wide association studies have clearly confirmed the role of all three in the progression of IBD (12, 20, 24, 35, 46, 50a, 52) . Moreover, hypoxia is present in the inflammatory foci, and through its transcription factors hypoxia-inducible factor (HIF)-1␣ and HIF-2␣ play an important role in inflammation and resolution of IBD (26, 27, 44, 53) . Currently, mechanisms leading to hypoxia in inflammatory foci are not clearly known and most likely involve vasculitis and edema (6) . Moreover, neutrophil migration into epithelial cells is critical in depleting local oxygen and activating HIF-1␣ (3). HIF-1␣ and HIF-2␣ in normoxic cells are rapidly degraded through oxygen-sensing enzymes prolyl hydroxylase domain proteins (PHD) (21, 22) . PHDs use oxygen as a substrate for hydroxylation (37) . In a cellular environment with sufficient oxygen, PHDs hydroxylate HIF-1␣ and HIF-2␣, leading to von Hippel-Lindau gene (VHL)-induced proteasomal degradation (21, 22) . Knockout mouse models and chemical inhibitors of PHDs demonstrate a robust activation of HIF signaling and underscore the importance of PHDs in the regulation of HIFs (37) .
HIF-1␣ and HIF-2␣ have distinct functions in intestinal inflammation. HIF-2␣ has been shown to increase inflammation through activation of epithelial inflammatory response (44, 53) . Several proinflammatory mediators are activated by HIF-2␣. Mice overexpressing HIF-2␣ specifically in the intestinal epithelial cells demonstrate spontaneous colitis and are significantly more susceptible to intestinal injury in several mouse models of colitis (53) . However, HIF-1␣ in intestinal epithelial cells is a potent protective factor through regulation of a battery of genes important in maintaining the epithelial tight barrier and mucosal immune response (3, 13, 26, 28, 34, 39, 48) . Currently no known adherens or tight junction proteins have been shown to be direct targets of HIF-1␣ in the intestine. However, several direct target genes of HIF-1␣ are expressed on the apical surface of intestinal epithelial cells and are critical in maintaining barrier integrity. Disruption of intestinal HIF-1␣ clearly demonstrates the central role of HIF-1␣-induced barrier function in IBD (26) .
PHD inhibitors or PHD knockout mice, which potently activate HIF-1␣, have been shown to be beneficial in several mouse models of colitis (8, 28, 39, 49) . However, the tumor-promoting effect of HIF-1␣ activators poses a major concern and limitation for their therapeutic use in the treatment of IBD. The colon tumor microenvironment shares several similar characteristics as the inflammatory foci in IBD. HIF-1␣ and HIF-2␣ are robustly increased in cancer (29, 42) . Chronic activation of HIF-2␣ in intestinal epithelial cells potentiates tumorigenesis in mouse models of colon cancer (54, 55) . Currently it is not known whether activation of HIF-1␣ can also increase colon carcinogenesis in mouse models. In the present study, we tested the hypothesis that activation of HIF-1␣ in intestinal epithelial cells would increase colon carcinogenesis. A mouse model of constitutively expressed HIF-1␣ in intestinal epithelial cells was characterized by whole-genome mRNA expression analysis. Moreover, the activation of HIF-1␣ in colon cancer was assessed in a sporadic intestinal tumor model and a colitis-associated colon cancer model. HIF-1␣ significantly increased glycolytic genes. However, constitutive activation of HIF-1␣ did not significantly alter tumor multiplicity, size, proliferation, or apoptosis. The data demonstrate that increase in HIF-1␣ in intestinal epithelial cells does not result in spontaneous tumor formation or further potentiate the progression of colon cancer.
MATERIALS AND METHODS

Animals and treatments. The Hif-1␣
LSL/LSL and littermate controls were previously described (53 Western blot analysis. For Western blot analysis, nuclear fractions were prepared from the epithelial cells of the small intestine and colon using a hypertonic buffer (200 mM sucrose, 10 Tris·HCl, and 2 mM EDTA with protease inhibitors). Nuclear proteins were then extracted using RIPA buffer, and proteins were resolved on SDS-PAGE. Proteins were then transferred onto a nitrocellulose membrane and probed with specific antibodies against HIF-1␣ (Santa Cruz Biotechnology, Santa Cruz, CA) and histone H3 (Cell Signaling Technology, Danvers, MA).
Histology, immunohistochemistry, and immunofluorescence. Mice were killed following a 2-h treatment of 100 mg/kg of 5-bromo-2-deoxyuridine (BrdU) (Sigma, St Louis, MO). Paraffin-embedded tissue sections (5 m) were deparaffinized in xylene and rehydrated in ethanol gradient. Immunohistochemical analysis was performed with antibodies for BrdU (Bu20a; eBioscience, San Diego, CA) and cleaved caspase 3 (cCasp3) (Cell Signaling Technology) as previously described (55) . Histological analysis was done on hematoxylin and eosin-stained paraffin sections.
Quantitative real-time RT-PCR. RNA was isolated and reverse transcribed as previously described (55) . For the AOM/DSS-treated normal tissue and tumor tissue following isolation, the RNA was further purified by lithium chloride precipitation. cDNA was quantified using SYBR green dye and run on a 7900HT Fast Real-Time RT-PCR system (Life Technologies, Carlsbad, CA) (primers listed in Table 1 ). Ct values were normalized to ␤-actin and expressed as fold difference from controls.
cDNA microarray analysis. RNA was extracted from colon mucosal scrapings from 8-wk-old Hif-1␣ LSL/LSL and littermate control mice and reverse transcribed. cDNA was hybridized to the Mouse Gene 1.1 ST Array Strips (Affymetrix, Santa Clara, CA), and data were analyzed as previously described (55) and compared with gene expression analysis from the colons of intestine-specific Vhl knockout (Vhl ⌬IE ) mice. The full data set is available on the GEO database accession number GSE55915 for the Hif-1␣ LSL/LSL mice and accession number GSE36091 for the Vhl ⌬IE mice. Statistics. Results are expressed as means Ϯ SD. P values were calculated by independent t-test, one-way ANOVA, Dunnett's t-test, and two-way ANOVA. P Ͻ 0.05 was considered significant.
RESULTS
Activation of intestinal HIF-1␣ does not lead to gross histological changes in the small intestine and colon. To directly understand the role of HIF-1␣ in the intestinal epithelium, the Hif-1␣
LSL/LSL mouse model was assessed (53) . These mice overexpress an oxygen-stable HIF-1␣ in intestinal epithelial cells (Fig. 1A) . The Hif-1␣ LSL/LSL mice do not have any overt phenotypes compared with littermate controls (53) . Histological analysis of the small intestine and the colon also demonstrated no obvious difference compared with wild-type mice (Fig. 1B) .
Global (Tables 2 and 3 ). As expected, several well-characterized target genes were induced, including genes involved in glycolysis, autophagy, and mitochondrial metabolism. The microarray data were compared with whole-genome mRNA analysis obtained from colons of Vhl ⌬IE mice (55) . Disruption of VHL led to a robust 
activation of HIF-1␣ and HIF-2␣ signaling, and the Hif-1␣
LSL/LSL mice demonstrated significant overlap with the Vhl ⌬IE mice with respect to genes that are increased ( Fig. 2A and Myosin, light polypeptide 7, regulatory Pfkfb3 (36) 6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 Nrn1
Neuritin 1 P4 ha1 (15) Procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), ␣1 polypeptide Stc2 (33) Stanniocalcin 2 Lpo Lactoperoxidase Greb1
Gene regulated by estrogen in breast cancer protein Mif (1) Macrophage migration inhibitory factor Pdk1 (30) Pyruvate dehydrogenase kinase, isoenzyme 1 Plod2 (16) Procollagen lysine, 2-oxoglutarate 5-dioxygenase 2 Car9 (51) Carbonic anhydrase 9 Grin1
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Bold font indicates known hypoxia-inducible factor (HIF)-1␣ target genes with the subsequent reference.
mice (25) . Similarly, PGE synthase (PGES1), the downstream gene of COX-1 important in the production of PGE 2 , was also not induced in the colon of Hif-1␣ LSL/LSL mice (Fig. 2B ). These data further confirm a previous study demonstrating a critical and specific role of HIF-2␣ in the regulation of the COX-2-mPGES1-PGE2 axis in colon cancer (54) .
Activation of intestinal HIF-1␣ does not increase sporadic colon tumorigenesis. Hif-1␣
LSL/LSL and littermate controls were crossed to the Apc min/ϩ mice. Apc min/ϩ mice have a truncated mutation at codon 850 of the murine Apc gene (47) . APC mutations are observed in over 80% of patients with sporadic colon cancer (10 (Fig. 3, A and B) . Similarly, HIF-1␣ activation did not lead to an increase in colon tumors in the Apc min/ϩ mice (Fig. 3, A and  C) . Also the tumors in the small intestine and colon were all adenomas, and no increase in progression was observed in Hif-1␣ LSL/LSL /Apc min/ϩ mice compared with littermate controls (Fig. 3A) . The tumors were further analyzed for proliferation and apoptosis by BrdU and cCASP3 staining, respectively. However, no significant difference in tumor proliferation or apoptosis was observed in the Hif-1␣ LSL/LSL /Apc min/ϩ compared with the littermate control mice (Fig. 4) .
Activation of intestinal HIF-1␣ does not increase colitisassociated colon cancer. The Apc
min/ϩ mice are not a robust model for colon cancer, and therefore a colitis-associated colon cancer (CAC) mouse model was assessed (5) . Body weight is a good index of systemic inflammation following DSS, and the littermate control mice had decreased body weight throughout the inflammatory and recovery phase compared with Hif-1␣ LSL/LSL mice (Fig. 5A) . These results demonstrated that activation of intestinal HIF-1␣ significantly protected from LSL/LSL and littermate control mice. C: qPCR analysis of cyclooxygenase (COX)-2 and prostaglandin E synthase 1 (PGES1). 6 mice were assessed per each group. Gene expression was normalized to ␤-actin, and each bar represents the mean value Ϯ SD. **P Ͻ 0.05, ***P Ͻ 0.01, compared with Hif-1␣ ϩ/ϩ mice. However, repeated exposures to DSS led to no significant difference in local inflammation in Hif-1␣ LSL/LSL and wildtype mice, as assessed by colon length and histology (Fig. 5,  B and C) . The expression of cytokines that are critical in the progression of colon cancer such as TNF-␣, IL-1␤, and IL-6 were assessed by qPCR (18, 38) . There was a significant decrease in TNF-␣, IL-1␤, and IL-6 in normal tissue from Hif-1␣ LSL/LSL mice compared with wild-type mice. In the tumors, there was a significant decrease in TNF-␣, but not IL-1␤ and IL-6 (Fig. 5D) . Moreover, HIF-1␣-dependent glycolytic and mitochondrial respiration genes important in cancer were significantly increased in tumor and normal tissue from Hif-1␣ LSL/LSL mice compared with littermate control mice (Fig. 5E ). Despite the increase in genes critical in tumor metabolism in the Hif-1␣ LSL/LSL mice, no difference in tumor number and tumor histology was observed compared with littermate controls (Fig. 6, A and B) . Moreover, tumor proliferation and apoptosis were similar in the Hif-1␣ LSL/LSL mice and littermate controls (Fig. 6C) .
DISCUSSION
HIF-1␣ and HIF-2␣ are the two major transcription factors critical for hypoxic-mediated transcriptional and translational cellular response. In the intestine, HIF-2␣ has recently been shown to increase inflammation and colon cancer (53-55). HIF-2␣ can directly regulate several proinflammatory genes.
TNF-␣ is a critical HIF-2␣ target gene in hypoxic inflammation (53) . HIF-1␣ activation in the intestine leads to barrier protection and a decrease in several proinflammatory cytokines in mouse models of colitis (26, 28) . However, the role of HIF-1␣ in cancer has led to concerns for the therapeutic use and efficacy of HIF-1␣ activators in IBD. The present data clearly demonstrate that, in mouse models of colon cancer, chronic activation of HIF-1␣ does not increase sporadic or inflammation-induced colon cancer. HIF-1␣ through a battery of target genes maintains barrier homeostasis and decreases inflammation in an acute colitis models (13, 26, 28, 34, 48) . Consistent with these data, a significant decrease in proinflammatory mediators and a protection in body weight loss following DSS treatment in Hif-1␣ LSL/LSL mice compared with littermates control mice were observed. Tumor-elicited inflammation in sporadic colon cancer and inflammation in CAC are due to dysregulation of the intestinal epithelial barrier and activation of proinflammatory response (19) . PHDs are critical in the activation of basal NF-B and also in limiting IL-1␤-induced NF-B (11, 40) . PHD inhibitors repress NF-B activity, which is a critical signaling pathway in the progression of sporadic and colitis-associated colon cancer (17) . PHD inhibitors may decrease tumor inflammation through two mechanisms, barrier protection and inhibition of NF-B signaling, and therefore would be beneficial in patients with colon cancer.
HIF-1␣ has been shown to have a major role in many aspects of tumor biology. A key function of hypoxia signaling in tumors is shifting the tumor metabolism to anaerobic glycolysis. HIF-1␣ is a direct regulator of glycolytic genes, which we confirm in vivo in the present study. Moreover, Ndufa4l2 is robustly increased in the colon of Hif-1␣ LSL/LSL mice, and this gene has been shown to be critical in limiting oxygen consumption and cellular adaptation of cells to hypoxia (41, 50) . The data demonstrate that the increase in these genes in normal colonic epithelial cells does not lead to cancer. Moreover, the increase in glycolytic and mitochondrial metabolic genes in adenomas does not increase the progression of early-stage tumors. Although most mouse models of colon cancer do not progress further than adenomas, it is possible that, in later stages of colon cancer, chronic activation of HIF-1␣ may potentiate progression. The microarray data from the Hif-1␣
LSL/LSL mice also demonstrated a significant increase in several novel genes that will require further experiments to confirm mechanisms of regulation by HIF-1␣. Several downregulated genes were also identified. However, unlike the genes that were induced, there was not a good correlation between the downregulated genes in the Hif-1␣ LSL/LSL mice and the Vhl ⌬IE mice. This may be due to the role of HIF-1␣ as a transcription factor that can directly bind to promoters and activate gene expression, whereas, to date, no known direct repressed HIF-1␣ target genes have been confirmed. Interestingly, fatty acid binding protein-1 (Fabp1) was inhibited in both mouse models. Fabp1 is highly expressed in the intestine, and deletion results in significant protection in adenoma formation in the Apc min/ϩ mice on 10% fat-containing diet (9). Although no protection was observed in adenoma formation in the Hif-1␣ LSL/LSL mice on standard chow, these data suggest that activation of HIF-1␣ may be beneficial in obesity-induced colon cancer.
The data provide strong evidence for the safe use of HIF-1␣ activators in colitis, without enhancing tumorigenesis. PHD inhibitors have been shown to be beneficial in mouse models of colitis and can activate the HIF response (8, 28, 39) . In cancer-derived cell lines, PHD inhibitors can activate both HIF-1␣ and HIF-2␣. In vivo in the intestine, PHD inhibitors primarily activate HIF-1␣ expression, thus limiting the proinflammatory role of HIF-2␣ (53) . Moreover, three PHDs exist, PHD 1, 2, and 3 (also referred to as Egln-2, -1, and -3, respectively). The most commonly used inhibitors are pan antagonists of PHDs (37) . However, through cell-based studies, it has been demonstrated that PHDs have different selectivity for HIF-1␣ and HIF-2␣ (37) . Thus the pharmacological intervention to treat colitis using PHD inhibitors that can specifically activate either HIF-1␣ or HIF-2␣ response is feasible. Indeed, AKB-4924 is a HIF-1␣-predominant PHD inhibitor, which is protective in mouse models of colitis (28) .
In summary, the data demonstrate that in vivo activation of intestinal HIF-1␣ does not impact tumorigenesis in two mouse models of colon cancer. This provides evidence for the safe use of PHD inhibitors in the treatment of ischemic and inflammatory disorders of the intestine. 
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